rring in ≥10% of Patients Receiving MEKINIST and at a Higher Incidence than in the Control Arma Adverse Reactions
MEKINIST
Chemotherapy
(N = 211)
(N = 99)
All Gradesb
Grades
3 and 4c
All Gradesb
Grades
3 and 4c
Skin and subcutaneous tissue disorders
Rash
57
8
10
0
Dermatitis acneiform
19
<1
1
0
Dry skin
11
0
0
0
Pruritus
10
2
1
0
Paronychia
10
0
1
0
Gastrointestinal disorders
Diarrhea
43
0
16
2
Stomatitisd
15
2
2
0
Abdominal paine
13
1
5
1
Vascular disorders
Lymphedemaf
32
1
4
0
Hypertension
15
12
7
3
Hemorrhageg
13
<1
0
0
aEvents included are higher in the trametinib arm compared with chemotherapy by ≥5% in overall incidence or by ≥2% Grade 3-4 adverse reactions higher in trametinib arm compared with chemotherapy.
b National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
c Grade 4 adverse reactions were limited to rash (n = 1) in trametinib arm and diarrhea (n = 1) in the chemotherapy arm.
d Includes the following terms: stomatitis, aphthous stomatitis, mouth ulceration, and mucosal inflammation.
e Includes the following terms: abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.
f Includes the following terms: lymphedema, edema, and peripheral edema.
g Includes the following terms: epistaxis, gingival bleeding, hematochezia, rectal hemorrhage, melena, vaginal hemorrhage, hemorrhoidal hemorrhage, hematuria, and conjunctival hemorrhage.
Other clinically important adverse reactions observed in ≤10% of patients (N = 329) treated with MEKINIST were:
Nervous System Disorders: Dizziness, dysgeusia.
Ocular Disorders: Vision blurred, dry eye.
Infections and Infestations: Folliculitis, rash pustular, cellulitis.
Cardiac Disorders: Bradycardia.
Gastrointestinal Disorders: Xerostomia.
Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis.
Table 3. Percent-Patient Incidence of Laboratory Abnormalities Occurring at a Higher Incidence in Patients Treated With MEKINIST in Trial 1 [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3 or 4)a] Preferred Term
MEKINIST
Chemotherapy
(N = 211)
(N = 99)
All Grades
Grades
3 and 4
All Grades
Grades
3 and 4
Increased Aspartate aminotransferase (AST)
60
2
16
1
Increased Alanine aminotransferase (ALT)
39
3
20
3
Hypoalbuminemia